ASRT - Assertio Therapeutics, Inc.
| Previous Close | 1.1700 |
| Open | 1.1700 |
| Bid | 1.1100 x 3200 |
| Ask | 1.1200 x 1100 |
| Day's Range | 1.1000 - 1.2100 |
| 52 Week Range | 0.6800 - 5.7600 |
| Volume | 879,085 |
| Avg. Volume | 2,905,909 |
| Market Cap | 90.766M |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9700 |
| Earnings Date | Nov 05, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
- Zacks
Assertio (ASRT) to Report Q4 Earnings: What's in Store?
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
- GlobeNewswire
Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt
LAKE FOREST, Ill., Feb. 19, 2020 -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated.
- Simply Wall St.
Did Changing Sentiment Drive Assertio Therapeutics's (NASDAQ:ASRT) Share Price Down A Painful 93%?
Assertio Therapeutics, Inc. (NASDAQ:ASRT) shareholders will doubtless be very grateful to see the share price up 61...
- Benzinga
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
- GlobeNewswire
Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (ASRT), today announced the closing of its previously disclosed definitive agreement (“Agreement”) with Collegium Pharmaceutical, Inc. (“Collegium”), pursuant to which Collegium has acquired the NUCYNTA® franchise of products from the Company. The Company also announced today that it has repaid in full its senior secured debt obligations. Under the terms of the agreement, Collegium paid Assertio $375.0 million in cash at closing, less royalties paid to Assertio in 2020.
- Benzinga
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- GlobeNewswire
Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (ASRT), today announced it has entered into a definitive agreement (“Agreement”) with Collegium Pharmaceutical, Inc. (“Collegium”) pursuant to which Collegium will acquire the NUCYNTA® franchise of products from the Company. Under the terms of the agreement, Collegium will pay Assertio $375.0 million in cash at closing, less royalties paid to Assertio in 2020. Collegium will also pay Assertio for certain inventories and equipment relating to the products.
- Zacks
Assertio (ASRT) Gains But Lags Market: What You Should Know
Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.
- Zacks
Assertio (ASRT) Dips More Than Broader Markets: What You Should Know
Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.
- Zacks
Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?
Is (ASRT) Outperforming Other Medical Stocks This Year?
- Zacks
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Assertio (ASRT) closed at $1.14, marking a -1.72% move from the previous day.
- Zacks
ASRT or PCRX: Which Is the Better Value Stock Right Now?
ASRT vs. PCRX: Which Stock Is the Better Value Option?
- GlobeNewswire
Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance
Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (ASRT), today announced the closing of its previously disclosed agreement (“Agreement”) with Alvogen, a global privately held pharmaceutical company, under which Alvogen will acquire and assume all responsibilities associated with the product Gralise® (gabapentin). Under the terms of the Agreement, Alvogen will pay Assertio a total value of $127.5 million. This includes $75.0 million in cash upon closing and the balance payable in the form of a royalty on the first $70.0 million in Gralise® net sales.
- Zacks
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
- Zacks
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).
- Zacks
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
- Zacks
ASRT vs. PCRX: Which Stock Is the Better Value Option?
ASRT vs. PCRX: Which Stock Is the Better Value Option?
- Zacks
Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Simply Wall St.
Need To Know: Assertio Therapeutics, Inc. (NASDAQ:ASRT) Insiders Have Been Buying Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- Insider Monkey
Hedge Funds Are Crazy About Assertio Therapeutics, Inc. (ASRT)
How do we determine whether Assertio Therapeutics, Inc. (NASDAQ:ASRT) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
- Zacks
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
- GlobeNewswire
Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million
Assertio Therapeutics, Inc. (“Assertio”) (ASRT), today announced it has entered into an agreement with Alvogen, a global privately held pharmaceutical company, under which Alvogen will acquire and assume all responsibilities associated with the product Gralise® (gabapentin). Under the terms of the agreement, Alvogen will pay Assertio a total value of $127.5 million. This includes $75 million in cash upon closing and the balance payable in the form of a royalty on the first $70 million in Gralise® net sales.
- Zacks
ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?
ASRT vs. PCRX: Which Stock Is the Better Value Option?
- GlobeNewswire
Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
LAKE FOREST, Ill., Nov. 26, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 31st Annual Piper.
